Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3

Journal of Neuroscience

Volumn 28, Issue 48, 2008, Pages 12713-12724

  Chen, Xi ^a   Tang, Tie Shan ^a   Tu, Huiping ^a,d   Nelson, Omar ^a   Pook, Mark ^b   Hammer, Robert ^a   Nukina, Nobuyuki ^c   Bezprozvanny, Ilya ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ataxin 3; Calcium signaling; Dantrolene; Machado Joseph disease; MJD1; Neurodegeneration; SCA3; Spinocerebellar ataxia type 3; Stereology; Transgenic mouse

Indexed keywords

ATAXIN 3; CALCIUM ION; DANTROLENE; INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR TYPE 1; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL LOSS; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG EFFECT; HEART FUNCTION TEST; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NERVE DEGENERATION; NONHUMAN; PONS ANGLE; PRIORITY JOURNAL; PROTEIN BINDING; SENSITIZATION; SPINOCEREBELLAR ATAXIA TYPE 3; SPINOCEREBELLAR DEGENERATION; SUBSTANTIA NIGRA; TRANSGENIC MOUSE;

ADULT; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BRAIN; CALCIUM SIGNALING; CELLS, CULTURED; DANTROLENE; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; MACHADO-JOSEPH DISEASE; MICE; MICE, INBRED C57BL; MUSCLE RELAXANTS, CENTRAL; MUTATION; NERVE DEGENERATION; NUCLEAR PROTEINS; PONS; RATS; RECOVERY OF FUNCTION; SUBSTANTIA NIGRA; TRANSCRIPTION FACTORS;

EID: 58149375272     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3909-08.2008     Document Type: Article

References (45)

1. Acikel M, Buyukokuroglu ME, Erdogan F, Aksoy H, Bozkurt E, Senocak H (2005) Protective effects of dantrolene against myocardial injury induced by isoproterenol in rats: biochemical and histological findings. Int J Cardiol 98:389-394.
2. Berg M, Bruhn T, Frandsen A, Schousboe A, Diemer NH (1995) Kainic acid-induced seizures and brain damage in the rat: role of calcium homeostasis. J Neurosci Res 40:641-646.
3. Berridge MJ (1998) Neuronal calcium signaling. Neuron 21:13-26.
4. Bezprozvanny I, Hayden MR (2004) Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun 322:1310-1317.
5. 3- and calcium-gated channels from endoplasmic reticulum of cerebellum. Nature 351:751-754.
6. Bichelmeier U, Schmidt T, Hübener J, Boy J, Rüttiger L, Häbig K, Poths S, Bonin M, Knipper M, Schmidt WJ, Wilbertz J, Wolburg H, Laccone F, Riess O (2007) Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci 27:7418-7428.
7. Burnett B, Li F, Pittman RN (2003) The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet 12:3195-3205.
8. Burnett BG, Pittman RN (2005) The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc Natl Acad Sci U S A 102:4330-4335.
9. Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, Al-Mahdawi S, King RH, Pook MA, Huxley C, Chamberlain S (2002) YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 11:1075-1094.
10. Chai Y, Koppenhafer SL, Shoesmith SJ, Perez MK, Paulson HL (1999) Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 8:673-682.
11. Coutinho P, Andrade C (1978) Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 28:703-709.
12. Cummings CJ, Zoghbi HY (2000) Trinucleotide repeats: mechanisms and pathophysiology. Annu Rev Genomics Hum Genet 1:281-328.
13. 2+ release from intracellular stores in cultured cerebral cortical neurons. J Neurochem 56:1075-1078.
14. Gafni J, Munsch JA, Lam TH, Catlin MC, Costa LG, Molinski TF, Pessah IN (1997) Xestospongins: potent membrane permeable blockers of the inositol 1,4,5-trisphosphate receptor. Neuron 19:723-733.
15. Giannini G, Conti A, Mammarella S, Scrobogna M, Sorrentino V (1995) The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. J Cell Biol 128:893-904.
16. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP (1999) Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med 5:101-106.
17. Gusella JF, MacDonald ME (2000) Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 1:109-115.
18. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi I, Kimura J, Narumiya S, Kakizuka A (1994) CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8:221-228.
19. Kaznacheyeva E, Lupu VD, Bezprozvanny I (1998) Single-channel properties of inositol (1,4,5)-trisphosphate receptor heterologously expressed in HEK-293 cells. J Gen Physiol 111:847-856.
20. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F (2004) Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia 59:364-373.
21. Makarewicz D, Ziemińska E, Łazarewicz JW (2003) Dantrolene inhibits NMDA-induced 45Ca uptake in cultured cerebellar granule neurons. Neurochem Int 43:273-278.
22. 2+ release. Trends Pharmacol Sci 16:356-359.
23. 2+ leak function of presenilin 1. J Clin Invest 117:1230-1239.
24. Nicastro G, Menon RP, Masino L, Knowles PP, McDonald NQ, Pastore A (2005) The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc Natl Acad Sci U S A 102:10493-10498.
25. Niebauer M, Gruenthal M (1999) Neuroprotective effects of early vs. late administration of dantrolene in experimental status epilepticus. Neuropharmacology 38:1343-1348.
26. Paulson HL, Das SS, Crino PB, Perez MK, Patel SC, Gotsdiner D, Fischbeck KH, Pittman RN (1997a) Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 41:453-462.
27. Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, Das SS, Vig P, Mandel JL, Fischbeck KH, Pittman RN (1997b) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19:333-344.
28. Perez MK, Paulson HL, Pittman RN (1999) Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix. Hum Mol Genet 8:2377-2385.
29. Popescu BO, Oprica M, Sajin M, Stanciu CL, Bajenaru O, Predescu A, Vidulescu C, Popescu LM (2002) Dantrolene protects neurons against kainic acid induced apoptosis in vitro and in vivo. J Cell Mol Med 6:555-569.
30. Scheel H, Tomiuk S, Hofmann K (2003) Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum Mol Genet 12:2845-2852.
31. Schneider I, Reverse D, Dewachter I, Ris L, Caluwaerts N, Kuiperi C, Gilis M, Geerts H, Kretzschmar H, Godaux E, Moechars D, Van Leuven F, Herms J (2001) Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem 276:11539-11544.
32. Stevanin G, Dürr A, Brice A (2000) Clinical and molecular advances in autosomal dominant cerebellar ataxias: from genotype to phenotype and physiopathology. Eur J Hum Genet 8:4-18.
33. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39:227-239.
34. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 102:2602-2607.
35. Tang TS, Chen X, Liu J, Bezprozvanny I (2007) Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 27:7899-7910.
36. Tu H, Miyakawa T, Wang Z, Glouchankova L, Iino M, Bezprozvanny I (2002) Functional characterization of the type 1 inositol 1,4,5-trisphosphate receptor coupling domain SII(+/-) splice variants and the opisthotonos mutant form. Biophys J 82:1995-2004.
37. Tu H, Wang Z, Nosyreva E, De Smedt H, Bezprozvanny I (2005a) Functional characterization of mammalian inositol 1,4,5-trisphosphate receptor isoforms. Biophys J 88:1046-1055.
38. Tu H, Wang Z, Bezprozvanny I (2005b) Modulation of mammalian inositol 1,4,5-trisphosphate receptor isoforms by calcium: a role of calcium sensor region. Biophys J 88:1056-1069.
39. Verkhratsky A (2005) Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev 85:201-279.
40. Wang G, Sawai N, Kotliarova S, Kanazawa I, Nukina N (2000) Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum Mol Genet 9:1795-1803.
41. Ward A, Chaffman MO, Sorkin EM (1986) Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 32:130-168.
42. Wei H, Perry DC (1996) Dantrolene is cytoprotective in two models of neuronal cell death. J Neurochem 67:2390-2398.
43. Wu J, Tang T, Bezprozvanny I (2006) Evaluation of clinically-relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci Lett 407:219-223.
44. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J (2006) Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. J Biol Chem 281:33477-33486.
45. Zoghbi HY, Orr HT (2000) Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23:217-247.